Author

P. Morakis

Observed name: P Morakis

Observed institution: Krebsregister Baden-Württemberg

OpenAlex ID: A5070202000

MO16.03: Sleeve Resection vs Pneumonectomy in NSCLC: Survival Benefit by Age, Nodal Status, and Resection Completeness

2026 · T. Schneider, I. Surovtsova, et al. · Journal of Thoracic Oncology

160P Lymphadenectomy in clinically node-negative ovarian cancer (FIGO I-III): A population-based analysis from the Baden-Wuerttemberg Cancer Registry

2026 · H. Endres, I. Surovtsova, et al. · ESMO Open

PDF

474P Real-world outcomes of first-line endocrine therapy with or without CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: A cancer registry study

2026 · I. Surovtsova, P. Morakis · ESMO Open

312P Real-world treatment landscape of stage III NSCLC: Comparing cisplatin and carboplatin in curative-intent therapy

2026 · W.E.E. Eberhardt, I. Surovtsova, et al. · ESMO Open

PDF

437P Immunotherapy in ES-SCLC: Real-world impact of atezolizumab/durvalumab, radiotherapy, and metastatic burden across ECOG 0-2 patients

2026 · I. Surovtsova, W.E.E. Eberhardt, et al. · ESMO Open

PDF

55P Impact of KRAS/TP53 and KEAP1/STK11 co-mutations on immune checkpoint inhibitor outcomes for metastatic NSCLC patients: Insights from real-world data

2026 · D. Kokh, I. Surovtsova, et al. · ESMO Open

PDF

A0303 Effect of prior nephrectomy and bone metastases on real-world efficacy of ipilimumab/nivolumab and pembrolizumab with TKI in metastatic clear-cell RCC

2026 · I. Surovtsova, P. Morakis · European Urology

1886P Metastatic spread and PD-L1 expression co-determine benefit from pembrolizumab in advanced non-squamous NSCLC

2025 · I. Surovtsova, M. Thomas, et al. · Annals of Oncology

852P Evaluating neoadjuvant options in synchronous mCRC RAS mutated or right-sided RAS wild type: A real-world perspective

2025 · I. Surovtsova, T. Seufferlein, et al. · Annals of Oncology

1199P Primary surgery vs neoadjuvant chemotherapy in advanced ovarian, tubal, and peritoneal carcinoma: Real-world evidence from the cancer registry

2025 · P. Morakis, A. Pfob, et al. · Annals of Oncology

Molekulare Tumordiagnostik beim metastasierten Mammakarzinom in Baden-Württemberg – eine Registeranalyse

2025 · K Burtscher, I Surovtsova, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie

115P Comparing primary surgery and neoadjuvant chemotherapy for advanced ovarian, tubal, and peritoneal carcinoma: Insights from real-world data

2025 · I. Surovtsova, A. Pfob, et al. · ESMO Open

PDF

161P Oncologic outcomes of hypofractionated vs conventionally fractionated radiotherapy in breast cancer patients with an indication for regional nodal irradiation: A cancer registry study

2025 · A. Pfob, I. Surovtsova, et al. · ESMO Open

PDF

111P Impact of radiation therapy on survival of patients with soft tissue sarcomas of the extremities and trunk: A cancer registry study

2025 · A. Rimner, I. Surovtsova, et al. · ESMO Open

114P Real-world evidence of synovial sarcoma: Prognostic factors and therapeutic approaches from cancer registry data

2025 · I. Surovtsova, J.T. Thiel, et al. · ESMO Open

PDF

20P: Cancer registry-based real-world evidence confirms efficacy of treatments comparable to KEYNOTE-189/-407 and Impower-133

2025 · I. Surovtsova, W.E.E. Eberhardt, et al. · Journal of Thoracic Oncology

PDF

Clinical Outcomes with Pembrolizumab and Nivolumab in Resected Advanced Melanoma: Real-World Evidence

2025 · I. Surovtsova, T. Vogel, et al. · EJC Skin Cancer

PDF

P205 Comparative outcomes of partial vs. radical nephrectomy for localized renal carcinomas: Insights from real-world data

2024 · I. Surovtsova, T. Vogel, et al. · European Urology Open Science

69P Use of bevacizumab for patients with FIGO stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: A German cancer registry study

2024 · A. Pfob, I. Surovtsova, et al. · ESMO Open

PDF

Use of Chemotherapy and Loco-regional Therapy for Stage IA triple-negative Breast Cancer and their Association with Oncologic Outcomes: A Cancer Registry Study

2024 · A. Pfob, I. Surovtsova, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie

140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study

2024 · A. Pfob, I. Surovtsova, et al. · ESMO Open

PDF

Pembrolizumab in Kombination mit Chemotherapie beim metastasierten NSCLC: eine Analyse anhand von Real-World-Daten des Klinischen Landeskrebsregisters

2024 · J Häberlin, F Kanz, et al. · Pneumologie

Primärtumor- und Metastasenlokalisation, molekulares Profil und Therapie bei metastasiertem kolorektalem Karzinom: Einfluss auf das Überleben auf Basis von klinischen Landeskrebsregisterdaten

2023 · I. Surovtsova, D. B. Kokh, et al. · Zeitschrift für Gastroenterologie

Clinical characterization of HCC/CCA mixed cancers in a population-based cohort

2023 · A. Teufel, I. Rodriguez, et al. · Zeitschrift für Gastroenterologie

Downstaging des Lymphknotenstatus beim duktalen Adenokarzinom des Pankreas: Ergebnisse einer Analyse von Krebsregister-Daten zum Benefit einer neoadjuvanten Therapie

2023 · G. Szotyori-Artz, M. Schirmer, et al. · Zeitschrift für Gastroenterologie

Works count: 25

Citation count:

H-index:

I10-index: